New information on the clinical and molecular aspects of Rett syndrome has emerged at an accelerated pace since the identification of mutations in methyl-CpG-binding protein 2 gene (MECP2) was first reported in 1999. Recent reports not only present new insights into the clinical and molecular understanding of this unique disorder but also have important implications for the neurobiology beyond Rett syndrome.
Introduction
Rett syndrome is a neurodevelopmental disorder characterized by cognitive impairment, communication dysfunction, stereotypic movement disorder, and growth failure. It was first described in 1965 by Andreas Rett [1, 2] , an Austrian developmental pediatrician, and was recognized at the same time by Bengt Hagberg, a Swedish child neurologist. Rett syndrome occurs worldwide in all ethnic groups. Accurate incidence data are unavailable, but prevalence ranges from 1:10 to 20,000 females, exceeding that for PKU. Therefore, all healthcare providers who care for children should be able to recognize the features of Rett syndrome and request appropriate consultation.
The diagnosis of Rett syndrome requires fulfillment of consensus criteria established in 2001 [3] . Based on the rapid expansion of clinical expertise over the period of the preceding 2 decades, an international panel reviewed the existing criteria and reached the current consensus criteria for both classic and atypical Rett syndrome (Table 1) . Recently, mutations in the MECP2 (methylCpG-binding protein 2) gene were identified in females meeting these diagnostic criteria [4] . At present, more than 225 mutations have been identified in MECP2, although eight common mutations are found in approximately 70% of those fulfilling the consensus criteria. Interestingly, mutations in MECP2 have also been demonstrated in people with a wide range of phenotypic presentations, including normal female carriers, females with Angelman syndrome, and females with variant clinical patterns for Rett syndrome. In addition, mutations in MECP2 have been noted in males with a fatal encephalopathy, Klinefelter (47,XXY) syndrome, somatic mosaicism and Rett syndrome features, and familial X-linked mental retardation [5] [6] [7] .
This review provides an update on the clinical and molecular status of Rett syndrome based on reports appearing during the past year. These reports cover a variety of clinical aspects seen in Rett syndrome such as electrocardiographic features, scoliosis, and motor disabilities, and an expanded understanding of the molecular genetics and neurobiology of Rett syndrome, including exciting new findings emerging from studies in knockout and knockin animal models. During this period, two complementary reviews have provided detailed information on the current status of Rett syndrome in general and the clinical and molecular aspects in particular [8•,9•]. In addition, the development of clinical and molecular databases in a cooperative arrangement between the International Rett Syndrome Association and separate sites in Australia should facilitate the aggregation of information for wide-scale studies [10•].
Clinical progress
Management of the clinical issues related to Rett syndrome continues to pose challenges. The inability of those with Rett syndrome to express discomfort or localize pain represents a significant barrier to timely diagnosis and management of specific medical problems. For example, gall bladder dysfunction including gallstones has been demonstrated with a frequency exceeding that in the general population. Based on personal experience and reports to the International Rett Syndrome Association (Hunter, Personal communication, April 2004) , approximately 1% of those with Rett syndrome have gallbladder dysfunction requiring cholecystectomy. As such, the new awareness of possible gall bladder disturbance and the known difficulties with constipation and gastroesophageal reflux against a background of unexplained irritability, suggestion of abdominal discomfort, or changes in behavior patterns should trigger a careful assessment of gastrointestinal and genitourinary tracts.
Hand function, both gross and fine motor skills, is markedly impaired in Rett syndrome. The predominance of left-handedness has been recognized for many years. Recently, Umansky et al. [11•] reported that from a cohort of 145 Australian participants with Rett syndrome ranging in age from 2 to 24 years, one third had left-hand preference, 41% right-hand preference, and 26% no preference. In the general population, more than 80% demonstrate right-hand preference.
Scoliosis and osteopenia are well-recognized components of Rett syndrome. Evaluation of bone obtained at the time of surgery for scoliosis revealed both a reduction of bone volume and a reduced rate of bone formation [12•]. Concerns about QT segment prolongation, ranging from 35% in younger females and increasing to as much as 50% among older people, has been noted in the past. Three recent reports address cardiac issues, with one demonstrating a correlation between plasma serotonin levels and cardiac dysautonomia [14] , another showing a correlation between lower plasma levels of nerve growth factor and QTc interval prolongation greater than 0.44 seconds [15] , and the third reporting severe sinus bradycardia in a child with normal QT parameters [16] .
Hearing loss is also common in Rett syndrome. Approximately one third of 81 participants in one study manifested diminished hearing function by auditory brainstem evoked responses with a trend to greater involvement in older people [17•] . The hearing loss was primarily sensorineural, and usually slight to mild, with none exhibiting severe loss. No correlation was found between hearing loss and the specific mutation, although in this study, only 27 had genetic testing, with 22 having a mutation in MECP2.
People with Rett syndrome have characteristic findings on EEG including background slowing, diminished or absent occipital dominant rhythm, and multifocal slow spike/wave activity. However, the EEG pattern in some children resembles that more commonly seen in Angelman syndrome [18, 19] . Indeed, females with the clinical appearance of Angelman syndrome may have mutations in MECP2 such that in those instances in which the diagnosis of Angelman syndrome cannot be confirmed by appropriate testing, one should strongly consider MECP2 testing.
Finally, people with Rett syndrome demonstrate some features that overlap with those of children with autism spectrum disorder. However, careful assessment should differentiate the two. Although eye contact and socialization may appear limited in both disorders, children with autism do not demonstrate the degree of gross and fine motor impairment seen in Rett syndrome and do not have hand stereotypies typically seen in Rett syndrome. After the period of regression, girls with Rett syndrome may actually have intense gaze and be quite social. Similarly, recent data suggest that people with Rett syndrome have higher scores on the Autism Behavior Checklist Sensory and Relating subscales than females with severe and profound mental retardation, suggesting that it is possible to differentiate people in these two categories through established testing modalities [20•].
Molecular advances
The discovery of mutations in the transcription repressor gene MECP2 in 1999 as the cause of Rett syndrome opened broad new vistas for study. Presently, more than 80% of females meeting the consensus criteria for Rett syndrome have mutations in this gene. MiltenbergerMiltenyi and Laccone [21••] provided a comprehensive update of the 218 mutations from more than 2100 people with Rett syndrome reported to date. Among those with mutations, the great majority (∼80%) represent single nucleotide changes, with the remainder small-scale deletions (∼17%) or insertions (∼3%). However, among the specific mutations, deletions or insertions represent ∼60% of the total. These small-scale deletions are clustered in the C-terminal region of MECP2. Regardless of the mechanism, these mutations lead to loss of function or a protein product with diminished stability. The standard methodology for mutation detection is based on polymerase chain reaction (PCR) amplification with subsequent sequencing of MECP2 coding exons. However, this method has proven to be inadequate because it will not detect large-scale deletions or rearrangements in MECP2, which have now been reported in several girls with Rett syndrome. Schollen et al. Multiplex ligation-dependent probe amplification has also been used for the detection of large deletions, as recently reviewed [24] . Using multiplex ligationdependent probe amplification, Erlandson et al. [25••] identified deletions in three of 11 females with classic Rett syndrome, but none in variant forms of Rett syndrome. As such, the identification of large-scale deletions not detected by standard PCR methodology provides an explanation, in part, for the 15 to 20% of females with classic Rett syndrome for whom a mutation has not been detected previously.
Recently, a novel splice variant of MECP2 was reported by Mnatzakanian et al. [26••] , leading to a second MeCP2 isoform. This isoform has now been named MeCP2_e1, whereas the isoform originally identified is now named MeCP2_e2. MeCP2_e1 arises from an ATG initiation codon in exon 1, which had been considered previously to be noncoding. The resulting protein is 12 amino acids longer than MeCP2_e2. MeCP2_e2 arises from an ATG initiation codon in exon 2, although no mutations have yet been identified in this exon. Mnatzakanian et al. [26••] found exon 1 mutations in two of 19 people with classic Rett syndrome lacking mutations elsewhere in MECP2. In addition, these authors noted that MeCP2_e1 is more than 10 times more abundant in brain than its previously recognized isoform.
Mutation analysis in females with atypical Rett syndrome or in other people with severe cognitive impairment and Rett-like behavior has yielded much lower rates of mutations in MECP2, namely, less than 50% of females with atypical Rett syndrome and less than 5% of males with clinical features consistent with Rett syndrome. The recent report of Hagberg et al. [27•] provides an excellent example of a young adult woman who does not meet consensus criteria for Rett syndrome but does satisfy consensus criteria for variant Rett syndrome. This woman learned to walk and speak at normal time points, but did have evidence of ataxia, dyspraxia, and hand stereotypies, placing her within the spectrum of Rett syndrome variants. Genetic testing revealed a 44 nucleotide deletion in the C-terminal region.
Two interesting reports detail the association of Rett syndrome with chromosomal abnormalities. Hammer et al. [28•] described a female with X trisomy (47,XXX), atypical Rett syndrome, and a de novo mutation in MECP2. She derived two identical X chromosomes from her mother. X chromosome inactivation (XCI) studies with peripheral lymphocytes indicated skewing such that only 14% of cells expressed the paternal X. Although the parental origin of the abnormal X chromosome could not be determined, it seems likely by virtue of the mild phenotype that it came from the father. Pescucci et al. [31•] found a missense mutation in a male with severe mental retardation along with dystonia, fine motor apraxia, and progressive spastic quadriparesis. Similar presentations had been described previously. Gomot et al. [32•] found variability of phenotypic expression among males from three unrelated families with three different mutations in MECP2. In one family, a Cterminal deletion was accompanied by variable (mild to severe) but nonprogressive mental retardation and relatively preserved motor function. In the two remaining families, two different missense mutations resulted in poor motor coordination and written language skills and mild nonprogressive mental retardation. Kleefstra et al.
[33••] examined MECP2 in 92 females with mental retardation and normal fragile X testing, 63 males and females with features of Angelman syndrome but normal methylation studies, and 98 males and females with Prader-Willi syndrome with normal methylation. Among the females with normal fragile X testing, one MECP2 mutation was found, whereas no mutations were identified in people with Prader-Willi syndrome. However, in the Angelman syndrome cohort, a MECP2 mutation was found in one female with classic Rett syndrome features, and a male was found to have somatic mosaicism for a MECP2 mutations. Conversely, Bourdon et al. [34•] failed to identify MECP2 mutations in a group of 354 males with mental retardation and normal fragile X testing.
In summary, MECP2 gene testing should be performed in females with features of classic and variant Rett syndrome; in infants, especially males with unexplained progressive encephalopathy; in males with features of Rett syndrome; in children with features of Angelman syndrome with normal genetic testing; and in children with familial X-linked mental retardation and normal fragile X testing. Although the overall yield may be less than 5%, the benefit of expanding the phenotypes associated with MECP2 mutations is significant.
Phenotype-genotype correlation
It has been recognized for more than 2 decades that the spectrum of clinical involvement among females with Rett syndrome is quite broad, ranging from severe involvement with little normal development to relatively preserved speech and gross motor function and somewhat preserved fine motor skills. Huppke et al. studied the developmental patterns of 120 females with MECP2 mutations and confirmed this broad spectrum of clinical involvement [35•].
In addition, efforts are ongoing to develop phenotypegenotype correlations, being mindful that XCI will modify the effect of specific mutations [36•]. The importance of XCI in Rett syndrome was highlighted previously by the report of Krepischi et al. [37] , noting an increased frequency of skewed XCI in peripheral lymphocytes of females with Rett syndrome (15/23) compared with four of 22 mothers and six of 30 controls. Conversely, in a study of 24 adolescent and adult females with both classic and atypical Rett syndrome, Smeets et al. [38•] noted no skewing of XCI associated with milder involvement. They did confirm previous reports that truncating mutations in proximal portions of the gene produced more severe involvement, although the number of nonsense mutations was small. They also noted that the missense mutation R133C was associated with prominent autistic features, whereas the missense mutation R306C resulted in slower progression. In contrast, Naidu et al. [ severity scale and demonstrated that the R306C mutation, among five common MECP2 mutations, resulted in a significantly milder phenotype. Although the number was small, females expressing the R133C mutation did not demonstrate a milder phenotype as had been reported and C-correlate. Conversely, C-terminal mutations did not yield a more severe phenotype. In addition, these authors noted that females with a combination of later onset of regression and less severe deceleration in rate of head growth had lower overall clinical severity score.
X chromosome inactivation patterns have been studied in one of the mouse models of Rett syndrome. Young and Zoghbi [42••] demonstrated that XCI in this model, which represents a known human mutation for Rett syndrome, is significantly skewed in favor of the wild-type allele. In primary neuronal cultures, neurons expressing the normal allele appear to have a selective advantage. In female mice with preferential XCI of the mutant allele, the Rett syndrome phenotype was diminished considerably. The authors conclude that these data support the critical role of MeCP2 for neuronal viability and raise the possibility in humans that such skewing could result in females with MECP2 mutations but with reduced clinical involvement and certainly absence of the Rett syndrome profile.
Supporting the notion of the importance of MeCP2 for neuronal viability, Luikenhuis et al. [43••] inserted a neuron-specific promoter controlled Mecp2 (murine nomenclature) transgene into their Rett syndrome knockout model. Mutant animals expressing the transgene did not differ from their wild-type siblings-that is, they were rescued from Rett syndrome. Interestingly, overexpression of Mecp2 is deleterious in that wild-type animals that also had the transgene developed significant motor dysfunction with ataxia and tremors and failure to thrive, although longevity was not impaired.
Neurobiology of MeCP2 and Rett syndrome
The role of MeCP2 in normal brain development remains elusive [44•] . The protein first appears at 10 to 14 weeks of gestation in the brain stem and subplate neurons of the cerebral cortex in humans, but it is not found at any time in glial cells and is not present in neural progenitors or in the germinal matrix. In elegant studies using both normal human brain and that derived from females with Rett syndrome, Armstrong et al. [45••] detailed the ontogeny of MeCP2 during human development from 10 weeks of gestation to 33 years in normal subjects and from 6 to 41 years in people with Rett syndrome. Four of 14 brains from those with Rett syndrome lacked mutations in MECP2. In all brains from girls with Rett syndrome, MeCP2 was reduced throughout the brain, with the greatest reductions in brain stem and thalamus. Because of low levels of immunoreactivity for MeCP2 in hippocampus and cerebellum, no comments could be made on these regions. The absence of MeCP2 in glial cells and in neuronal precursors in normal brain and the marked reduction of MeCP2 in brain neurons, especially brain stem and thalamus, support the concept that MeCP2 plays a critical role in the maturation and maintenance of neurons and is not involved in neuronal proliferation. Similar results in rat brain have been reported [46•]. MeCP2 expression was greatest in cerebral cortex and olfactory nuclei, with little expression in basal ganglia and hippocampus. Unlike in humans, little expression was detected before birth. Unfortunately, brain stem and cerebellum were not studied. Ronnett et al. The mechanism of formation of this form and its role in neuronal function remains to be determined.
Striking similarities exist in the neuropathologic findings in brains from people with Rett syndrome, Angelman syndrome, ASD, Down syndrome, and fragile X syndrome with respect to reduced cell packing density (Rett syndrome and ASD) and abnormal dendrites (Rett syndrome, Angelman syndrome, Down syndrome, and fragile X syndrome). C-terminal MeCP2 expression in brain is significantly reduced not only in Rett syndrome (n = 5/5) but also in Angelman syndrome (n = 1/1) and both increased (n = 1/4) and decreased (3/4) in ASD [51••] . The authors conclude that the expression of MeCP2 is controlled by several pathways.
The importance of DNA methylation in the regulation of gene expression is well known and has particular relevance to MeCP2 and Rett syndrome [52•]. MeCP2 binds to methyl-CpG islands in promoter regions of an unknown number and type of genes, resulting in silencing of their expression. One of the critical domains of MeCP2 is the methyl-binding domain (MBD) that links the protein to the methyl-CpG islands. As such, muta-tions in the MeCP2 MBD in people with Rett syndrome would be expected to alter this binding function. Kudo et al. [53••] 
Conclusion
The pace of advancement in understanding of the clinical, molecular, and neurobiologic elements of Rett syndrome has quickened dramatically in the nearly 4 years since the identification of mutations in the MECP2 gene as causal for this unique disorder. During this period, appreciation of the clinical aspects of Rett syndrome has expanded, and the phenotypic spectrum associated with mutations in MECP2 has extended well beyond Rett syndrome to include a number of overlapping clinical phenotypes including Angelman syndrome, fragile X syndrome, and ASDs. In parallel, basic research on the role of MeCP2 in neuronal development in animal models and the search for related genes have expanded understanding of the pathogenesis of Rett syndrome specifically and developmental neurobiology in general.
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